Abstract
Polymeric particles with intricate morphologies and properties have been developed based on bioinspired designs for applications in regenerative medicine, tissue engineering, and drug delivery. However, the fabrication of particles with asymmetric functionalities remains a challenge. Janus polymeric particles are an emerging class of material with asymmetric functionalities; however, they are predominantly spherical in morphology, made from non-biocompatible materials, and made using specialized fabrication techniques. We therefore set out to fabricate nonspherical Janus particles inspired by high aspect ratio filamentous bacteriophage using polycaprolactone polymers and standard methods. Janus high aspect ratio particles (J-HARPs) were fabricated with a nanotemplating technique to create branching morphologies selectively at one edge of the particle. J-HARPs were fabricated with maleimide handles and modified with biomolecules such as proteins and biotin. Regioselective modification was observed at the tips of J-HARPs, likely owing to the increased surface area of the branching regions. Biotinylated J-HARPs demonstrated cancer cell biotin receptor targeting, as well as directional crosslinking with spherical particles via biotin-streptavidin interactions. Lastly, maleimide J-HARPs were functionalized during templating to contain amines exclusively at the branching regions and were dual-labeled orthogonally, demonstrating spatially separated bioconjugation. Thus, J-HARPs represent a new class of bioinspired Janus material with excellent regional control over biofunctionalization.
Keywords: bioinspired materials, Janus, bioconjugation, particle, nanotechnology, polymer, biotin
Graphical Abstract

Inspired by filamentous bacteriophage, polymeric high aspect ratio particles with asymmetric Janus functionalities (J-HARPs) were fabricated with branched morphologies at one end. Maleimide-bearing J-HARPs were conjugated with biomolecules, demonstrating regional modification at branching sites. Biotinylated J-HARPs demonstrated cancer cell targeting and directional crosslinking with microspheres. Bifunctional J-HARPs with orthogonal reactive handles were fabricated for dual bioconjugation with regiospecificity.
1. Introduction
Bioinspired materials have seen increasing use for applications in nanotechnology and biomedicine. Intricate materials have been reported using systems inspired by naturally occurring bioadhesives, light harvesting systems, and self-assembling biomaterials, among others.[1–6] Bioinspired polymeric materials and particles have been engineered with diverse morphologies and physicochemical properties for applications such as tissue engineering and drug delivery.[7,8] However, the design of polymeric particles with asymmetric distributions of functionalities remains a challenge. Many examples of materials with asymmetric regions of functionality are found throughout natural systems.[9] Proteins have regiospecific functionalities and biochemical properties, which lead to controlled assembly dynamics, enzymatic active sites, and specific binding domains of antibodies.[10,11] Viruses such as filamentous bacteriophage contain multivalent displays of peptides on one end of the virus particle to enable directional binding to targets.[12] Such natural systems have been engineered by researchers to create protein-based materials with regiospecific bioconjugate chemistries, or to create biotechnologies such as ELISAs and phage display.[9–13] However, asymmetric biofunctionalities remain difficult to achieve using exclusively synthetic materials.
Janus particles are an emerging class of synthetic material with asymmetric properties that have shown promise for applications in drug delivery, diagnostic medicine, and tissue engineering.[14,15] Janus materials have attracted attention for their ability to display multiple biofunctional handles with regional control to enable improved material biointerfaces,[16,17] as cells can respond to biological cues in gradient-dependent manners.[17,18] In the field of drug delivery, Janus particles have shown promise in dual drug delivery, enabling the co-delivery of multiple bioactive compounds with independent rates of release.[19–21] “Theranostic” Janus materials have attracted attention for their abilities to better control multiple cargo conjugations onto a single particle carrier.[15,22] Also within the field of drug delivery, Janus particles have enabled the development of micro- and nanomotors, with gas-producing catalysts at one end of a particle to enable directional active motion and the penetration of particles through biological barriers.[23] These Janus particles can be made from either inorganic or polymeric materials and fabricated through a variety of methods including modification of particles at surface interfaces, directed material assemblies, microfluidics, electrojetting, and biphasic Pickering emulsions.[14,15,24,25] While some Janus particles have been developed using hybrid platforms of biodegradable synthetic and biologically derived materials,[26] the majority of Janus particles are spherical in morphology and composed of inorganic non-biodegradable materials or specially synthesized polymers. We therefore set out to develop using standard fabrication techniques and commercially available biodegradable polymers, a new class of nonspherical Janus particle inspired by the regional functionalities of high aspect ratio filamentous bacteriophage.
To create these bacteriophage-inspired Janus particles, we utilized polycaprolactone high aspect ratio particles (HARPs), an emerging class of materials which we recently reported on for applications in local immunomodulation and regenerative engineering.[27–29] By adapting the HARP nanotemplating fabrication process,[27] asymmetric Janus HARPs (J-HARPs) were fabricated with high surface area branching morphologies at one edge of the particle. J-HARPs bearing maleimide conjugation handles were fabricated and functionalized with biomolecules such as proteins and biotin, with predominant modification observed at the branched region of the J-HARPs, owing to its increased surface area. We further demonstrated the versatility of J-HARPs by fabricating particles with separate regions of orthogonal reactivities and regioselectively labeled HARPs with two different fluorescent cargos. Janus HARPs therefore represent a novel class of bioinspired material, made from readily available and biodegradable components, and could see use in diverse biomedical applications.
2. Results and Discussion
2.1. Fabrication and Regioselective Labeling of Janus High Aspect Ratio Particles
Janus high aspect ratio particles (J-HARPs) were fabricated from biodegradable polycaprolactone (PCL) polymers using a nanotemplating technique. We previously reported on the use of nanotemplating to fabricate symmetric PCL HARPs of 10–20 μm in length and 200 nm in dimeter.[27,29] PCL was spun cast into films and heated in contact with 20 nm porous anodic aluminum oxide (AAO) Anodisc templates, causing melted PCL to travel through the AAO pores via capillary action. Anodiscs with 20 nm porosities only contain 20 nm pores on one edge of the disc, with 200 nm diameter pores occupying the majority of the Anodisc template lengths.[30] Thus, when fabricating HARPs, we have previously observed particles with 200 nm diameters even when HARP formation is initiated at the 20 nm side of the AAO template.[27] This is due to extended templating times of 2–3 h, which provides sufficient time for PCL to pass through the 20 nm branched porous region of the Anodiscs. We therefore hypothesized that if a limited templating occurs, PCL polymers would be retained partially within the 20 nm branching porous region of the AAO template (Figure 1a). Upon solidification, AAO etching, and HARP purification, particles would then bear those branching morphologies at one end, resembling the morphologies of high aspect ratio filamentous bacteriophage. Fabrication conditions were screened to facilitate limited templating and J-HARP formation, with optimized conditions observed using 10 kDa PCL templated at 60 °C for 30 min prior to removal of the Anodiscs from heat and subsequent cooling and etching. Helium ion microscopy (HIM) revealed asymmetric Janus HARPs with a branched morphology observed exclusively at one edge of the particles (Figure 1b).
Figure 1.

Fabrication and characterization of Janus HARPs. (a) Janus HARPs are fabricated using a nanotemplating technique. Partial templating at the 20 nm side of a porous AAO template leads to asymmetric HARP formation, with branching morphologies at one end of the particle. (b) Helium ion microscopy images of Janus HARPs, confirming asymmetric branching. Larger HIM images are available in the Supporting Information.
To engineer J-HARPs for biomolecule functionalization, PCL2k-maleimide[27] was incorporated at 20 wt% into the J-HARP backbone during fabrication. FITC-labeled bovine serum album (FITC-BSA) was used to test material bioconjugation efficiencies (Figure 2a), as BSA contains a reactive thiol to facilitate maleimide-thiol addition.[31] Interestingly, predominant modification was observed at one edge of the J-HARPs, corresponding to the end with branching morphologies (Figure 2b,c). This is likely due to the higher surface area on the branching region, which can increase the exposure of maleimide groups and subsequent bioconjugation efficiencies.[32,33] The regiospecific branching at one edge of the J-HARP therefore enabled asymmetric modification of the particle in a gradient manner, with highest degrees of FITC-BSA observed at the branched region. Modification was quantified through analysis of fluorescence intensities along the length of the J-HARPs, and a steep gradient of modification was observed starting at approximately 1 μm from the J-HARP edge (Figure 2d), corresponding to the point at which branching morphologies begin to be observed on the particles. A set of symmetric HARPs with maleimide handles were fabricated by templating PCL from the 200 nm side of the AAO template and reacted with FITC-BSA (Figure S3). As expected, symmetric modification with no detectable fluorescence gradient was observed for symmetric HARPs, owing to the lack of high surface area regions on the particles. Additionally, minimal nonspecific adsorption of FITC-BSA to J-HARPs lacking maleimide handles was observed (Figure S4), confirming that the maleimide-thiol reaction led to the observed asymmetric fluorescence. Thus, J-HARPs not only have asymmetric morphologies, but also regiospecific reactive handles for bioconjugation in a gradient manner.
Figure 2.

Asymmetric functionalization of Janus HARPs. (a) J-HARPs were fabricated containing 20 wt% PCL-maleimide. Reaction of maleimide J-HARPs with FITC-BSA yielded BSA-conjugated J-HARPs, with maximal conjugation observed at the branched region of the particles. Asymmetric modification was confirmed via fluorescence microscopy images of FITC-BSA J-HARPs at 20x (b) and 100x (c) magnification. Larger fluorescence microscopy images are available in the Supporting Information. (d) Quantification of J-HARP modification via analysis of fluorescence intensity across the length of J-HARPs (n=20).
2.2. Biotinylated J-HARPs for Cancer Targeting and Directed Colloidal Assemblies
To enable the binding of filamentous phage-inspired J-HARPs to targets of interest, maleimide-bearing J-HARPs were functionalized with thiol-PEG3k-biotin polymers to enable the multivalent display of biotin at the branched edge of J-HARPs. J-HARPs were also fabricated to include Nile red fluorophores embedded within the PCL core for fluorescence tracking of particles. Biotinylation was confirmed through the incubation of J-HARPs with Cy5-modified streptavidin (STV). STV binding to J-HARPs was observed predominantly at the edge of the particles (Figure 3a–c). The high regioselective gradient of STV binding is likely due to the combination of initial thiol-biotin gradient formation, similar to that observed with FITC-BSA conjugation, followed by an additional binding step of biotin with STV.
Figure 3.

Formation of biotin J-HARPs for cancer cell targeting. J-HARPs with maleimide handles were fabricated with Nile red dye encapsulated in the PCL core and were modified with thiol-PEG3k-biotin. (a) Incubation of Biotin J-HARPs with Cy5-Streptavidin (STV, green) revealed asymmetric STV binding to J-HARPs in a gradient manner. (b) Nile red fluorescence in pink and (c) overlay of the fluorophores reveal homogenous Nile red distribution with asymmetric biotinylation of J-HARPs. (d) Confocal fluorescence microscopy z-axis projection of biotin J-HARPs incubated with lung cancer A549 cells, which overexpress biotin receptors. Strong interactions and binding events were observed between A549 cells and biotin J-HARPs. A549 cells were stained with CellMask Deep Red Plasma membrane stain (green), and J-HARPs were fabricated to contain Nile red fluorophores (pink). (e) Binding efficiencies of J-HARPs for A549 cells (biotin receptor positive) and HEK-293 cells (biotin receptor negative) were quantified, and increased cancer cell targeting was observed for biotin J-HARPs to A549 cells when compared to unmodified J-HARPs (**p = 0.0027) or when incubated with HEK-293 cells (* p = 0.037).
Biotin receptors are overexpressed on a variety of cancer cell types, and thus biotin is a promising biomolecule to facilitate cancer targeting for applications in diagnostic medicine and drug delivery.[34,35] To determine whether biotin J-HARPs can act as cancer cell-targeting particles, A549 lung cancer cells that overexpress biotin receptors[35,36] were incubated with either nonfunctionalized fluorescent J-HARPs or with biotinylated fluorescent J-HARPs. We observed strong interactions between biotin J-HARPs and A549 cancer cells (Figure 3d), while moderate interactions were observed for unmodified J-HARP controls (Figure S5). Binding efficiencies were quantified, and increased cancer cell targeting was observed for biotin J-HARPs when compared to unmodified J-HARPs (Figure 3e, p = 0.0027). To confirm that binding was mediated through biotin receptor targeting, HEK-293 cells, which have lower levels of biotin receptor expression,[36] were incubated with both unmodified and biotinylated J-HARPs. Reduced binding was observed for biotin J-HARPs to HEK-293 cells when compared to A549 cells (p = 0.037), thus indicating that the observed increase in cell binding by biotin J-HARPs is due to receptor interactions.
In addition to facilitating targeted binding to cancer cells, biotin-HARPs were also evaluated for their ability to form directional crosslinks with biotinylated spherical particles. Fluorescent polymeric microspheres were fabricated from poly(lactic-co-glycolic acid) (PLGA) and biotin-PEG-PLGA block co-polymers. Biotin J-HARPs were incubated with STV to form STV J-HARPs, washed to remove excess STV, and then incubated with spherical biotin microparticles (Figure 4a). Interactions between STV-functionalized J-HARPs and biotin microparticles were observed via fluorescence microscopy (Figure 4b), with directional binding predominantly occurring at the tip of the J-HARPs. J-HARPs therefore show promise in enabling directional crosslinking and will be further engineered to facilitate controllable assembly dynamics for mixed particle co-assemblies, which have demonstrated potential for applications in tissue engineering and regenerative medicine.[29,37]
Figure 4.

Directional particle crosslinking with biotinylated Janus HARPs. (a) Biotin J-HARPs were incubated with STV to form asymmetric STV J-HARPs, which were then incubated with biotin-functionalized spherical microparticles (Biotin MP) to form directional crosslinks. (b) Fluorescence microscopy of STV J-HARPs (pink) incubated with biotin MPs (green). Biotin MPs were observed in close proximity to J-HARPs, with interactions predominantly observed at the tip of the J-HARPs, indicating directional crosslinking.
2.3. Orthogonal Dual Modification of Bifunctional J-HARPs
One of the features of biological materials most difficult to create using synthetic polymers is heterogeneous regions of chemical functionality. To create Janus materials with regional bifunctionality, PCL was mixed at 20 wt% with PCL-maleimide and templated into AAO from the 20 nm end and cooled to form J-HARPs within the template pores. 8-Mercaptooctylamine was then added to the 20 nm side of the AAO template to react with PCL-maleimide and selectively functionalize J-HARPs with amines only at the branched end that was exposed at the AAO surface (Figure 5a). We hypothesized that this fabrication process would lead to bifunctional J-HARPs with amine functionalities at the branched end and maleimide functionalities distributed throughout the remaining J-HARP backbone. To validate this approach, bifunctional J-HARPs were incubated with an IRDye-680 NHS ester to react with J-HARP amines followed by incubation with FITC-BSA to react with maleimides. We observed regional fluorescence of dual-modified J-HARPs, with IRDye-680 observed only at the branched tips of the J-HARPs and FITC fluorescence observed throughout the remaining particle backbone (Figure 5b–d). In situ modification of J-HARPs within AAO templates therefore provides a straightforward method to fabricate particles with regional chemical handles for subsequent conjugation reactions and regiospecific functionalization.
Figure 5.

Bifunctional HARP fabrication and dual labeling. (a) Maleimide-bearing J-HARPs were modified within the AAO template after HARP solidification but prior to AAO etching. This in situ conjugation led to J-HARPs with amine functional handles at the branching end and maleimide groups throughout the remainder of the particle. (b) Dual fluorescent labeling of bifunctional J-HARPs through conjugation with IR680-NHS esters (pink) and FITC-BSA (green) revealed regiospecific fluorescent labeling. FITC (c) and Cy5 (d) channels reveal gradient FITC-BSA modification and regioselective IR680 labeling at J-HARP edges.
3. Conclusion
The design and fabrication of polymeric particles with asymmetric Janus functionalities has been primarily limited to the fabrication of spherical particles using non-biodegradable or specially synthesized polymers. Here we report a straightforward nanotemplating approach to fabricate high aspect ratio particles with Janus functionalities (J-HARPs) using biodegradable polycaprolactone polymers. J-HARPs were fabricated with branching morphologies at one edge of the particle, inspired by the morphologies and functionalities of high aspect ratio filamentous bacteriophage. Owing to the increased surface area of the branching region of J-HARPs, we were able to achieve regioselective labeling and functionalization of J-HARPs with biomolecules such as proteins and biotin. Lastly, we utilized in situ modification of J-HARPs within AAO templates to facilitate orthogonal bifunctionalities for dual labeling with regiospecific fluorescence. Taken together, these studies highlight J-HARPs as a new class of Janus material with regional biofunctionalities that could see use in applications such as drug delivery and diagnostic medicine.
4. Experimental Section/Methods
General Methods and Instrumentation:
Unless otherwise noted, all reagents were purchased from commercial sources. 10 kDa PCL was used for the fabrication of J-HARPs. PCL2k-maleimide was prepared as previously described.[27] PLGA (75:25 L:G, 35,000–45,000 Mn) and PLGA-PEG-Biotin (50:50 L:G Mw 10,000 Da PLGA 2,000 Da PEG, PolySciTech) were used for the fabrication of biotinylated PLGA microparticles. J-HARPs were imaged using a Zeiss Helium Ion Microscope (HIM) at the University of California Berkeley Biomolecular Nanotechnology Center (Berkeley, California). Samples were sputter coated with gold-palladium at 10 mA for 45 s prior to imaging. All fluorescence microscopy studies were conducted at the UCSF Nikon Imaging Center using a Nikon Ti spinning disk confocal microscope for cell studies and a Nikon 6D epifluorescence microscope for J-HARP bioconjugation studies.
Janus HARP Fabrication:
Janus high aspect ratio particles (J-HARPs) were fabricated by adapting a previously reported nanotemplating technique.[27] 100 mg/ml solution of 10 kD PCL in trifluoroethanol was spun cast onto a glass wafer at 1000 rpm for 30 s, followed by heating at 150 °C to increase homogeneity of the surface coating. After cooling, an anodized aluminum oxide (AAO) membrane (Anodisc 37 mm, 20 nm pore size) was placed atop the PCL film and transferred to a hot plate preheated to 60 °C. Templating occurred for 30 min, followed by removal and cooling of the AAO templates. The AAO templates were then etched in 5 M NaOH, and shaken at room temperature for 25 minutes, followed by sonication in a bath sonicator for 10 minutes. The solution was then diluted 2-fold in ddH2O and centrifuged at 3000 rpm for 10 minutes to cause J-HARP sedimentation. NaOH supernatant was removed and the J-HARPs were washed 2–3 times with cold ddH2O, followed by PBS, and finally with 2–4 additional ddH2O washes until a neutral pH was measured. J-HARPs were then passed through a 40 μm cell strainer to remove large aggregates and stored in ddH2O at 4 °C. To fabricate fluorescent J-HARPs, Nile red dye was added to the PCL/TFE solution at 0.5 mg/ml prior to spin casting and templating. PCL-maleimide was added to the PCL/TFE solution at 20 wt% relative to 10 kDa PCL prior to spin casting and templating.
Biotin-Microparticle Fabrication:
PLGA (75:25 L:G, 35,000–45,000 Mn) and PLGA-PEG-Biotin were dissolved together in 2 mL dichloromethane (DCM) at 100 mg/ml PLGA and 10 mg/ml PLGA-PEG-biotin, followed by addition of DiR fluorophore (200 μL of 1 mg/ml solution in ethanol). 1 mL of 0.2% aqueous solution of poly(vinyl alcohol) (PVA) was then added to the polymer solution and sonicated using a probe sonicator for 25 sec (5 sec on, 10 sec off; 30% amplitude), followed by addition of 6 mL 1% PVA. The solution was then transferred to a beaker and gently stirred while adding an additional 10 mL of 1% PVA. The solution was stirred for an additional 2–3 h at room temperature to allow for DCM evaporation. The particle solution was then spun down at 2000 rpm for 5 min to sediment the particles. PLGA particles were washed with several rounds of 1% PVA solution and lyophilized to yield 18.6 mg of fluorescent biotinylated microparticles.
J-HARP Modification and Functionalization:
J-HARPs were suspended in a solution of 25 mM potassium phosphate buffer pH 7, to which was added an equal volume of 200 μM solution of thiol-bearing biomolecules (FITC-BSA, biotin-PEG-thiol). The solution was mixed together and gently shaken at room temperature for 2 h. J-HARPs were then pelleted via centrifugation at 10k rpm for 5 min and washed 3–4 times with PBS. For directional crosslinking experiments, a solution of biotin J-HARPs was added to equal volume of 50 μM STV and incubated for 2–3 h prior to centrifugation and washing. STV J-HARPs were then added to an equal volume of biotinylated PLGA microparticles and mixed together while shaking overnight prior to imaging.
Cell Culture Studies:
A549 lung cancer cells were cultured in F-12K media with L-glutamine, supplemented with 10% fetal bovine serum (FBS) and penicillin/streptomycin, and incubated at 37 °C and 5% CO2. HEK-293 cells were cultured in DMEM media with L-glutamine, supplemented with 10% FBS and penicillin/streptomycin. Cells were trypsinized, plated at 10,000 cells per well in 96 well plates and incubated overnight. After overnight incubation, media was replaced with 100 μL media containing J-HARPs or J-HARP controls and incubated for 6 h. Media was then removed and cells were washed with PBS prior to imaging and/or fluorescence quantification. For imaging experiments, A549 lung cells were stained with CellMask Deep Red Plasma membrane stain (ThermoFisher). To quantify J-HARP binding percents, positive control wells of cells in PBS were doped with appropriate concentrations of J-HARPs, identical to the concentration of J-HARPs added initially to represent 100% binding efficiencies.
Statistical Analysis:
For image analysis and quantification, 20 HARPs were selected from multiple images for gradient quantification. ImageJ was used to evaluate fluorescence intensity across a 10 μm length of HARP, starting at one edge of the particle. Background fluorescence intensities were determined by measuring the fluorescence of an unoccupied region of the image, and backgrounds were subtracted from all data points. For each HARP analyzed, the maximal fluorescence data point was determined, and all other data points within that set were converted to % maximal fluorescence in relation to the highest fluorescence data point. % Max Fluorescence data were then averaged, and data were plotted as mean % Max Fluor ± standard deviation. For cell studies, 4 samples per group were analyzed and data were plotted as mean ± standard deviation. Statistical significance was determined using a one-way ANOVA followed by Tukey’s multiple comparisons with Graphpad Prism software (*p<0.05, **p<0.01).
Supplementary Material
Acknowledgements
J.A.F. was supported by the UCSF HIVE postdoctoral fellowship. T.A.D. acknowledges funding by the National Institutes of Health (HL137209 and CA244438).
Footnotes
Supporting Information
Supporting Information is available from the Wiley Online Library or from the author.
References
- [1].Lee H, Lee BP, Messersmith PB, Nature 2007, 448, 338. [DOI] [PubMed] [Google Scholar]
- [2].Li J, Celiz AD, Yang J, Yang Q, Wamala I, Whyte W, Seo BR, Vasilyev NV, Vlassak JJ, Suo Z, Mooney DJ, Science (80-. ) 2017, 357, 378. [DOI] [PMC free article] [PubMed] [Google Scholar]
- [3].Choi MS, Yamazaki T, Yamazaki I, Aida T, Angew. Chemie - Int. Ed 2003, 43, 150. [DOI] [PubMed] [Google Scholar]
- [4].Miller RA, Presley AD, Francis MB, J. Am. Chem. Soc 2007, 129, 3104. [DOI] [PubMed] [Google Scholar]
- [5].Knight AS, Zhou EY, Francis MB, Zuckermann RN, Adv. Mater 2015, 27, 5665. [DOI] [PubMed] [Google Scholar]
- [6].Cui H, Webber MJ, Stupp SI, Biopolymers 2010, 94, 1. [DOI] [PMC free article] [PubMed] [Google Scholar]
- [7].Fisher OZ, Khademhosseini A, Langer R, Peppas NA, Acc. Chem. Res 2010, 43, 419. [DOI] [PMC free article] [PubMed] [Google Scholar]
- [8].Finbloom JA, Sousa F, Stevens MM, Desai TA, Adv. Drug Deliv. Rev 2020, DOI 10.1016/j.addr.2020.06.007. [DOI] [PMC free article] [PubMed] [Google Scholar]
- [9].Sarikaya M, Tamerler C, Jen AKY, Schulten K, Baneyx F, Nat. Mater 2003, 2, 577. [DOI] [PubMed] [Google Scholar]
- [10].Dimarco RL, Heilshorn SC, Adv. Mater 2012, 24, 3923. [DOI] [PubMed] [Google Scholar]
- [11].De La Rica R, Matsui H, Chem. Soc. Rev 2010, 39, 3499. [DOI] [PMC free article] [PubMed] [Google Scholar]
- [12].Kehoe JW, Kay BK, Chem. Rev 2005, 105, 4056. [DOI] [PubMed] [Google Scholar]
- [13].Finbloom J, Aanei I, Bernard J, Klass S, Elledge S, Han K, Ozawa T, Nicolaides T, Berger M, Francis M, Nanomaterials 2018, 8, 1007. [DOI] [PMC free article] [PubMed] [Google Scholar]
- [14].Walther A, Müller AHE, Chem. Rev 2013, 113, 5194. [DOI] [PubMed] [Google Scholar]
- [15].Tran LTC, Lesieur S, Faivre V, Expert Opin. Drug Deliv 2014, 11, 1061. [DOI] [PubMed] [Google Scholar]
- [16].Yi Y, Sanchez L, Gao Y, Lee K, Yu Y, Chem. Mater 2017, 29, 1448. [DOI] [PMC free article] [PubMed] [Google Scholar]
- [17].Kehr NS, Motealleh A, Schäfer AH, ACS Appl. Mater. Interfaces 2016, 8, 35081. [DOI] [PubMed] [Google Scholar]
- [18].Li C, Ouyang L, Pence IJ, Moore AC, Lin Y, Winter CW, Armstrong JPK, Stevens MM, Adv. Mater 2019, 31, e1900291. [DOI] [PMC free article] [PubMed] [Google Scholar]
- [19].Hwang S, Lahann J, Macromol. Rapid Commun 2012, 33, 1178. [DOI] [PubMed] [Google Scholar]
- [20].Garbuzenko OB, Winkler J, Tomassone MS, Minko T, Langmuir 2014, 30, 12941. [DOI] [PMC free article] [PubMed] [Google Scholar]
- [21].Wang F, Pauletti GM, Wang J, Zhang J, Ewing RC, Wang Y, Shi D, Adv. Mater 2013, 25, 3485. [DOI] [PubMed] [Google Scholar]
- [22].Misra AC, Bhaskar S, Clay N, Lahann J, Adv. Mater 2012, 24, 3850. [DOI] [PubMed] [Google Scholar]
- [23].Srivastava SK, Clergeaud G, Andresen TL, Boisen A, Adv. Drug Deliv. Rev 2019, 138, 41. [DOI] [PubMed] [Google Scholar]
- [24].Dendukuri D, Pregibon DC, Collins J, Hatton TA, Doyle PS, Nat. Mater 2006, 5, 365. [DOI] [PubMed] [Google Scholar]
- [25].Pang X, Wan C, Wang M, Lin Z, Angew. Chemie - Int. Ed 2014, 53, 5524. [DOI] [PubMed] [Google Scholar]
- [26].Quevedo DF, Habibi N, Gregory JV, Hernandez Y, Brown TD, Miki R, Plummer BN, Rahmani S, Raymond JE, Mitragotri S, Lahann J, Macromol. Rapid Commun 2020, 41, 2000425. [DOI] [PubMed] [Google Scholar]
- [27].Zamecnik CR, Lowe MM, Patterson DM, Rosenblum MD, Desai TA, ACS Nano 2017, 11, 11433. [DOI] [PMC free article] [PubMed] [Google Scholar]
- [28].Zamecnik CR, Levy ES, Lowe MM, Zirak B, Rosenblum MD, Desai TA, Biomaterials 2020, 230, DOI 10.1016/j.biomaterials.2019.119626. [DOI] [PMC free article] [PubMed] [Google Scholar]
- [29].Finbloom JA, Demaree B, Abate AR, Desai TA, Adv. Funct. Mater 2020, DOI 10.1002/adfm.202005938. [DOI] [PMC free article] [PubMed] [Google Scholar]
- [30].Atchison SN, Burford RR, Darragh TA, Polym. Int 1991, 26, 261. [Google Scholar]
- [31].Finbloom JA, Han K, Slack CC, Furst AL, Francis MB, J. Am. Chem. Soc 2017, 139, 9691. [DOI] [PubMed] [Google Scholar]
- [32].Spicer CD, Pashuck ET, Stevens MM, Chem. Rev 2018, 118, 7702. [DOI] [PMC free article] [PubMed] [Google Scholar]
- [33].Algar WR, Prasuhn DE, Stewart MH, Jennings TL, Blanco-Canosa JB, Dawson PE, Medintz IL, Bioconjug. Chem 2011, 22, 825. [DOI] [PubMed] [Google Scholar]
- [34].Maiti S, Paira P, Eur. J. Med. Chem 2018, 145, 206. [DOI] [PubMed] [Google Scholar]
- [35].Heo DN, Yang DH, Moon HJ, Lee JB, Bae MS, Lee SC, Lee WJ, Sun IC, Kwon IK, Biomaterials 2012, 33, 856. [DOI] [PubMed] [Google Scholar]
- [36].Ren WX, Han J, Uhm S, Jang YJ, Kang C, Kim JH, Kim JS, Chem. Commun 2015, 51, 10403. [DOI] [PubMed] [Google Scholar]
- [37].Caldwell AS, Aguado BA, Anseth KS, Adv. Funct. Mater 2019, 1907670, 1. [DOI] [PMC free article] [PubMed] [Google Scholar]
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.
